Merus N.V. (MRUS) 30-day option implied volatility amid price movement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
Merus N.V. (MRUS) PT Raised to $84 at BMO Capital
May 28, 2024 11:51 AM EDTBMO Capital analyst Etzer Darout raised the price target on Merus N.V. (NASDAQ: MRUS) to $84.00 (from $58.00) while maintaining a Outperform rating.
The analyst comments "We're updating our model following MRUS's pre-ASCO petosemtamab plus pembrolizumab combination update in 1L head and neck cancers... More
BMO Capital Reiterates Outperform Rating on Merus N.V. (MRUS)
May 28, 2024 8:13 AM EDTBMO Capital analyst Etzer Darout reiterated an Outperform rating and $58.00 price target on Merus N.V. (NASDAQ: MRUS).
The analyst comments "MRUS announced updated data from the Phase 1/2 trial evaluating petosemtamab/ pembrolizumab in 1L HNSCC patients, reporting a 67% ORR in 24 patients, including a 75%... More
